These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. Sawyers CL Cancer Cell; 2002 Feb; 1(1):13-5. PubMed ID: 12086882 [TBL] [Abstract][Full Text] [Related]
24. A hope for the future. Silver RT Cancer Invest; 2003 Jun; 21(3):486. PubMed ID: 12901295 [No Abstract] [Full Text] [Related]
25. Implications of signal transduction inhibition for the treatment of chronic myeloid leukemia. Sawyers CL Semin Hematol; 2001 Jul; 38(3 Suppl 8):1-2. PubMed ID: 11526594 [No Abstract] [Full Text] [Related]
26. STI571: a magic bullet? Verweij J; Judson I; van Oosterom A Eur J Cancer; 2001 Oct; 37(15):1816-9. PubMed ID: 11576833 [No Abstract] [Full Text] [Related]
27. Chronic myeloid leukemia: the race is yet to be won. Cortes J CMAJ; 2012 May; 184(8):857-8. PubMed ID: 22271914 [No Abstract] [Full Text] [Related]
28. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. Wang L; Pearson K; Pillitteri L; Ferguson JE; Clark RE Br J Haematol; 2002 Sep; 118(3):771-7. PubMed ID: 12181044 [TBL] [Abstract][Full Text] [Related]
29. STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia. O'Dwyer ME; Druker BJ Lancet Oncol; 2000 Dec; 1():207-11. PubMed ID: 11905636 [TBL] [Abstract][Full Text] [Related]
30. Imatinib for chronic myeloid leukaemia: a NICE mess. Barbour V Lancet; 2001 Nov; 358(9292):1478. PubMed ID: 11705557 [No Abstract] [Full Text] [Related]
31. Use and limitations of imatinib mesylate (Glivec), a selective inhibitor of the tyrosine kinase Abl transcript in the treatment of chronic myeloid leukaemia. Knight GW; McLellan D Br J Biomed Sci; 2004; 61(2):103-11. PubMed ID: 15250677 [TBL] [Abstract][Full Text] [Related]
36. From the Food and Drug Administration. Schwetz BA JAMA; 2001 Jul; 286(1):35. PubMed ID: 11434814 [No Abstract] [Full Text] [Related]
37. [Tyrosine kinase inhibitors in the therapy of chronic myeloid leukaemia]. Grzybowska-Izydorczyk O; Góra-Tybor J; Robak T Postepy Hig Med Dosw (Online); 2006; 60():490-7. PubMed ID: 17013368 [TBL] [Abstract][Full Text] [Related]
38. Pregnancy outcomes in patients with chronic myeloid leukemia treated with imatinib mesylate: short report from a developing country. Iqbal J; Ali Z; Khan AU; Aziz Z Leuk Lymphoma; 2014 Sep; 55(9):2109-13. PubMed ID: 24237577 [TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials. Zackova D; Klamova H; Muzik J; Cmunt E; Racil Z; Machova Polakova K; Dvorakova D; Jurcek T; Razga F; Cetkovsky P; Dusek L; Mayer J Leuk Lymphoma; 2013 Oct; 54(10):2310-3. PubMed ID: 23373966 [No Abstract] [Full Text] [Related]
40. Position paper on imatinib mesylate in chronic myeloid leukaemia. O'Brien SG; Rule SA Br J Haematol; 2002 Oct; 119(1):268-72. PubMed ID: 12358935 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]